Baltimore (1)

Chapel Hill (1)

Indianapolis (1)

Nashville (1)

Philadelphia (1)

Washington (1)

HER2 Negative (1)

Invasive Breast Cancer (1)

Stage IV Breast Cancer (1)

Triple Negative Breast Cancer (1)

Active, not recruiting (1)

phase 2 (1)

Vanderbilt-Ingram Cancer Center (1)

Genentech, Inc. (1)

National Cancer Institute (NCI) (1)

atezolizumab (1)

carboplatin (1)

laboratory biomarker (1)

quality-of-life assessment (1)

drug (1)

other (1)

Other (1)

Interventional (1)

her2 negative

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Dec 1, 2022